文献速递角膜与眼表疾病

正电子发射断层扫描用于眼用药物制剂开发及角膜滞留特性表征

Positron Emission Tomography for the Development and Characterization of Corneal Permanence of Ophthalmic Pharmaceutical Formulations.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

本研究旨在描述正电子发射断层扫描/计算机断层扫描(PET/CT)作为无创工具用于局部眼用制剂生物滞留药代动力学研究的效用。研究以含结冷胶和κ-卡拉胶(0.82%重量/体积)并标记18氟(18F)放射性示踪剂(18F-FDG和18F-NaF)的局部眼用制剂,用专用小动物PET/CT评估其角膜生物滞留性,并与标记相同化合物的水溶液比较。结果显示两种制剂的眼部药代动力学存在差异:接触1.5小时后90%的水凝胶仍留在眼表,而对照溶液仅剩69%;眨眼在试验方法中起非常重要的作用;18F-FDG点眼对人角膜上皮细胞既无刺激性也无细胞毒性。作者结论认为小动物PET与18F放射性示踪剂用于眼用制剂眼部药代动力学是可行的,并可能成为未来人体眼部药代动力学研究的安全方法。

要点

  • 接触1.5小时后90%的水凝胶仍留在眼表,对照溶液仅剩69%。
  • 眨眼在本试验方法中起非常重要的作用。
  • 18F-FDG点眼对人角膜上皮细胞无刺激性、无细胞毒性。

核心结论

  • 小动物PET与18F放射性示踪剂用于眼用制剂眼部药代动力学是可行的,并可能成为未来人体眼部药代动力学研究的安全方法。

研究设计与样本

  • 用专用小动物PET/CT评估含结冷胶和κ-卡拉胶(0.82%重量/体积)并标记18F放射性示踪剂(18F-FDG和18F-NaF)的局部眼用制剂的角膜生物滞留性,并与标记相同化合物的水溶液比较。
  • 在重建的PET图像上手动勾画感兴趣区(ROI)以定量眼部放射性浓度,通过局部点眼后不同时间测定放射性浓度确定制剂的生物滞留性。
  • 另进行细胞及离体安全性检测以评估所用操作的安全性。

主要发现

  • 两种制剂的眼部药代动力学存在差异。
  • 接触1.5小时后90%的水凝胶仍留在眼表,而对照溶液仅剩69%。
  • 观察到眨眼在试验方法中起非常重要的作用。
  • 18F-FDG点眼对人角膜上皮细胞既无刺激性也无细胞毒性。

临床怎么用

  • 作者认为小动物PET与18F放射性示踪剂用于眼用制剂眼部药代动力学是可行的,并可能成为未来人体眼部药代动力学研究的安全方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This work is aimed at describing the utility of positron emission tomography/computed tomography (PET/CT) as a noninvasive tool for pharmacokinetic studies of biopermanence of topical ocular formulations. METHODS: The corneal biopermanence of a topical ophthalmic formulation containing gellan gum and kappa carragenan (0.82% wt/vol) labeled with 18Fluorine (18F) radiotracers (18F-FDG and 18F-NaF) was evaluated by using a dedicated small-animal PET/CT, and compared with the biopermanence of an aqueous solution labeled with the same compounds. Regions of interest (ROIs) were manually drawn on the reconstructed PET images for quantifying the radioactivity concentration in the eye. The biopermanence of the formulations was determined by measuring the radioactivity concentration at different times after topical application. Additionally, cellular and ex vivo safety assays were performed to assess the safety of the performed procedures. RESULTS: Differences were observed in the ocular pharmacokinetics of the two formulations. After 1.5 hours of contact, 90% of the hydrogel remained in the ocular surface, while only 69% of the control solution remained. Furthermore, it was observed that flickering had a very important role in the approach of the trial. The application of 18F-FDG in the eye was neither irritating nor cytotoxic for human corneal epithelial cells. CONCLUSIONS: The use of small-animal PET and 18F radiotracers in ocular pharmacokinetics of ophthalmic formulations is feasible and could be a safe method for future ocular pharmacokinetic studies in humans.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Fernández-Ferreiro A, Silva-Rodríguez J, Otero-Espinar FJ, et al. Positron Emission Tomography for the Development and Characterization of Corneal Permanence of Ophthalmic Pharmaceutical Formulations. Invest Ophthalmol Vis Sci. 2017. PMID: 28146242. doi:10.1167/iovs.16-20766

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。